Velpatasvir / Sofosbuvir

Common brands: Epclusa, Ribavirin, Lasix, Zestril, Neurontin

Top reporter: Gilead Sciences, Inc.

Hepatitis C Virus NS5A Inhibitor [EPC]Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]Nucleoside Analog Antiviral [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Loop Diuretic [EPC]
12,698
Total Reports
3,113
Serious Reports
576
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (4.54%)

Patient Demographics

Male
6,942
Female
5,210

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Velpatasvir / Sofosbuvir.

# Reaction Reports % of Total
1 FATIGUE 2,622
20.2%
2 HEADACHE 2,212
17.1%
3 NAUSEA 1,173
9.0%
4 DIARRHOEA 658
5.1%
5 DRUG INEFFECTIVE 546
4.2%
6 INSOMNIA 510
3.9%
7 HEPATITIS C 407
3.1%
8 TREATMENT FAILURE 329
2.5%
9 VOMITING 327
2.5%
10 DEATH 302
2.3%
11 DIZZINESS 285
2.2%
12 RASH 255
2.0%
13 PRODUCT DOSE OMISSION ISSUE 245
1.9%
14 ABDOMINAL DISCOMFORT 239
1.8%
15 INTENTIONAL DOSE OMISSION 217
1.7%
16 DYSPEPSIA 214
1.7%
17 DRUG DOSE OMISSION 202
1.6%
18 PAIN 201
1.6%
19 ASTHENIA 199
1.5%
20 PRURITUS 199
1.5%
21 PRODUCT DOSE OMISSION 184
1.4%
22 DECREASED APPETITE 176
1.4%
23 ABDOMINAL PAIN UPPER 175
1.4%
24 CONSTIPATION 173
1.3%
25 ARTHRALGIA 170
1.3%
26 DEPRESSION 161
1.2%
27 DYSPNOEA 156
1.2%
28 ABDOMINAL PAIN 150
1.2%
29 SOMNOLENCE 142
1.1%
30 ANXIETY 133
1.0%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.